By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GlycoMimetics, Inc. 

14915 Broschart Road, Suite 200

Rockville   Maryland  20850  U.S.A.
Phone: 301-738-1166 Fax:




Company News
GlycoMimetics, Inc. (GLYC) Data On GMI-1271 Treatment Of Acetaminophen-Triggered Liver Toxicity To Be Presented At “Digestive Disease Week” Conference 4/26/2016 12:30:06 PM
GlycoMimetics, Inc. (GLYC) Appoints ImmunoGen (IMGN) CEO Daniel Junius To Board Of Directors 3/21/2016 10:28:16 AM
GlycoMimetics, Inc. (GLYC) To Present New Preclinical Data On Its E-Selectin-CXCR4 Dual Antagonist At AACR Annual Meeting 2016 3/17/2016 10:51:25 AM
GlycoMimetics, Inc. (GLYC) Announces Initial Clinical Data From Phase I Portion Of Clinical Trial Of GMI-1271 In AML Patients 3/2/2016 10:30:03 AM
GlycoMimetics, Inc. (GLYC) Reports Fourth Quarter And Year-End 2015 Results 3/1/2016 11:55:40 AM
GlycoMimetics, Inc. (GLYC) To Present At 18th Annual BIO CEO & Investor Conference 2/2/2016 11:06:01 AM
GlycoMimetics, Inc. (GLYC) Poster Shows GMI-1271 Reverses Drug Resistance In Multiple Myeloma Models 12/7/2015 2:00:26 PM
GlycoMimetics, Inc. (GLYC) Presents At American Society of Hematology Meeting First-In-Human Data Showing Favorable Safety, Metabolic And Biomarker Profiles For GMI-1271 12/7/2015 1:58:39 PM
GlycoMimetics, Inc. (GLYC) Highlights Preclinical Data In Oral Presentation At American Society of Hematology Meeting Demonstrating Impact Of GMI-1271 On T Memory Stem Cells 12/7/2015 10:33:41 AM
GlycoMimetics, Inc. (GLYC) Presents Preclinical Data At American Society of Hematology Annual Meeting Showing GMI-1359 Enhances Efficacy Of Chemotherapy In FLT-3 AML Model 12/7/2015 10:32:16 AM